Increased cultivation capacity will enhance the Company’s ability to produce pharmaceutical grade psilocybin at scale DENVER, May 25, 2021 (GLOBE NEWSWIRE) — Mydecine Innovations Group (NEO: MYCO) (OTC: MYCOF) (FSE: 0NFA) (“Mydecine” or the “Company”), an emerging biopharma and life sciences company committed to the research, development, and acceptance of alternative nature-sourced medicine for…


Previous articlePT245 – Robin Carhart-Harris – Psychedelics, Entropy, and Plasticity
Next articlePharmaTher Files for FDA Orphan Drug Designation for Ketamine to Treat Lou Gehrig’s Disease